Proteome Sciences PLC AGM Statement (6438Z)

TIDMPRM

RNS Number : 6438Z

Proteome Sciences PLC

17 May 2023

17 May 2023

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Annual General Meeting (AGM) Statement

At the Company's AGM being held today at 12.00 noon, the Chairman, Christopher Pearce, will make the following statement:

"Proteome Sciences had a strong performance in the year ended 31 December 2022 with total revenue increasing by 52% to GBP7.78m (2021: GBP5.13m). Biomarker services grew by 45% to GBP2.75m and TMT(R)/TMTpro(TM) revenues increased 56% to GBP5.03m with adjusted EBITDA rising 79% to GBP2.43m. The cash position increased by GBP1.6m to GBP3.99m. These results include the costs incurred for the investment we have made in additional instrumentation and skilled personnel in our workforce, to promote the strategic decision to introduce our single cell proteomics ("SCP") platform in 2023 and to undertake the development of new and complementary range of chemical tags to our TMT(R)/TMTpro(TM) reagents. Both new offerings are expected to expand our growth in revenue and recognition of our expertise in the marketplace.

The Board is confident that the progress over the recent years has created an excellent platform for further development of the Group. Following the investment made over the last two years, a strong order book, new projects, high customer interest, our healthy cash position and recently announced expansion into the US, the Group has a strong base for 2023 and beyond. Proteome Sciences is well set to achieve a step-change in growth which gives the Board increased confidence that the business can continue to significantly grow revenue and EBITDA in the coming years."

For further information:

 
 
   Proteome Sciences plc 
 Dr. Mariola Soehngen, Chief Executive Officer   Tel: [phone] 
  Dr. Ian Pike, Chief Scientific Officer 
 Richard Dennis, Chief Commercial Officer 
  Abdelghani Omari, Chief Financial Officer 
 
 Allenby Capital Limited (Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter (Corporate      Tel: [phone] 
  Finance)                                        5656 
  Tony Quirke / Stefano Aquilino (Equity Sales 
  & Corporate Broking) 
 
 

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGMAFMLTMTBBBAJ

(END) Dow Jones Newswires

May 17, 2023 02:00 ET (06:00 GMT)